David King Stephens, MD
Epilepsy · Orange, CANPI 1700973633
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $351,549 of the $551,243 with a category attached, or 63.8%. 27 manufacturers reported payments, led by UCB, Inc. at 38.1% of the total. Among epilepsy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 855 payments — averaging $644.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$210K
- SK Life Science, Inc.$87K
- Neurelis, Inc.$80K
- Catalyst Pharmaceuticals, Inc.$49K
- Eisai Inc.$44K
- Ceribell, Inc.$31K
- plus $50K from 21 others
Across 23 payments — averaging $4730.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$83K
- Medtronic$22K
- Biogen$4K
- Neuropace, Inc.$430
What the payments were for
- Consulting fees$106,86619%
- Speaking & faculty fees$351,54964%
- Travel & lodging$72,56913%
- Food & beverage$20,2594%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 334 | $210,092 |
| SK Life Science, Inc. | 143 | $87,431 |
| Neurelis, Inc. | 125 | $80,383 |
| Catalyst Pharmaceuticals, Inc. | 42 | $48,520 |
| Eisai Inc. | 66 | $43,587 |
| Ceribell, Inc. | 4 | $30,750 |
| Neuropace, Inc. | 37 | $18,025 |
| Greenwich Biosciences, Inc. | 23 | $8,891 |
| Livanova USA, Inc. | 18 | $7,341 |
| Aquestive Therapeutics, Inc. | 8 | $5,824 |
| Shire North American Group Inc | 3 | $3,230 |
| UCB SA | 1 | $2,700 |
| Zimmer Biomet | 8 | $1,089 |
| UCB Biosciences Inc. | 2 | $1,050 |
| Medtronic(2 entities) | 5 | $871 |
| Jazz Pharmaceuticals Inc. | 7 | $807 |
| ZOLL Medical Corporation | 1 | $233 |
| Sunovion Pharmaceuticals Inc. | 15 | $138 |
| Neurocrine Biosciences, Inc. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $45 |
| Bausch Health US, LLC | 2 | $28 |
| Adamas Pharmaceuticals, Inc. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$111,192
- Fycompa$91,339
- VALTOCO$78,490
- XCOPRI$69,870
- Nayzilam$36,441
- Fintepla$33,261
- POCKET EEG DEVICE$18,600
- Cenobamate$13,950
- Ceribell Rapid Response EEG$12,150
- RNS Neurostimulator Kit$10,988
- Epidiolex$9,209
- VNS Therapy$7,129
- RNS System$6,481
- SYMPAZAN$4,770
- Vimpat$3,791
- ROSA$915
How this compares
$551,243 in reported general payments places this provider in the 95th percentile of 46 epilepsy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 100 | $2,837 |
| Lacosamide | 30 | $2,120 |
| Lamotrigine ErLamotrigine | 19 | $1,810 |
| Divalproex Sodium | 13 | $756 |
| Lamotrigine | 22 | $703 |
| Levetiracetam ErLevetiracetam | 15 | $256 |
| Clonazepam | 13 | $190 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Orange
- Mona SazgarOrange$222K
- Kurt QingOrange$7K
- Lilit MnatsakanyanOrange$3K
- Brian JungOrange$3K
- Doris DengOrange$3K
- Josef ParviziStanford$438K
- Kimford MeadorStanford$50K
- Robert FisherStanford$41K
- Martha MorrellStanford$17K
- George NuneArcadia$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.